RFXAP Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-18683

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP3-18683
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

Chromatin Immunoprecipitation (ChIP)

Label

Unconjugated

Antibody Source

Polyclonal Rabbit

Concentration

1 mg/ml

View all RFXAP Antibodies »

Product Specifications

Immunogen

Polyclonal antibody raised in rabbit against RFXAP (Regulatory factor X-associated protein), using the recombinant protein.

Clonality

Polyclonal

Host

Rabbit

Scientific Data Images for RFXAP Antibody

Chromatin Immunoprecipitation: RFXAP Antibody [NBP3-18683] - Figure 1 ChIP results obtained with the antibody directed against RFXAP ChIP assays were performed using NALM cells (a cell line derived from human pre-B leukemia), the antibody against RFXAP and optimized primer sets for PCR. Sheared chromatin from 2 million cells and respectively 5 and 7 ug of antibody were used per ChIP experiment. An anti-flag antibody (lane 2) was used as negative IP control. Figure 1 shows the result of the end-point PCR with primers for HLA_DRA, used as positive control (lower panel) and for HLA_DOB, used a negative PCR control (upper panel).

Applications for RFXAP Antibody

Application
Recommended Usage

Chromatin Immunoprecipitation (ChIP)

5-7 ug/IP
Application Notes
Please note that of the optimal antibody amount per IP should be determined by the end-user. We recommend testing 1-10 ug per IP.

Formulation, Preparation, and Storage

Purification

Affinity purified

Formulation

PBS

Preservative

0.05% Sodium Azide and 0.05% ProClin 300

Concentration

1 mg/ml

Shipping

The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles.

Background: RFXAP

The identification of transacting factors controlling major histocompatibility complex (MHC) class II gene transcription via the proximal enhancer of the promoter has been greatly facilitated by a genetic approach, namely, the analysis of cell lines that are characterized by regulatory defects abolishing transcription of these genes (Mach et al., 1996). Most of these MHC class II regulatory mutants are cell lines derived from patients suffering from MHC class II deficiency, also referred to as the bare lymphocyte syndrome type II, a rare autosomal recessive disorder characterized by the lack of constitutive and inducible MHC class II expression in all cell types and tissues. The genetic lesions responsible for this lack of expression lie not in MHC class II genes themselves, but in transacting regulatory genes required for their transcription (Mach et al., 1996). Durand et al. (1997) noted that at least 3 different complementation groups (groups A, B, and C) have been identified by means of somatic cell fusion experiments. the defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC class II promoters Durand et al. (1997) isolated a novel gene that encodes the 36-kD subunit of RFX. They called this subunit RFX-associated protein (RFXAP) because it is a subunit of the RFX complex and interacts with RFX5, yet it does not contain the characteristic RFX DNA-binding motif.

Alternate Names

regulatory factor X-associated protein, RFX DNA-binding complex 36 kDa subunit, RFX-associated protein

Gene Symbol

RFXAP

Additional RFXAP Products

Product Documents for RFXAP Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for RFXAP Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.